| Literature DB >> 33389359 |
Andrea Sonaglioni1, Michele Lombardo2, Gian Luigi Nicolosi3, Elisabetta Rigamonti2, Claudio Anzà4.
Abstract
During the COVID-19 pandemic, transesophageal echocardiography (TEE) for left atrial appendage thrombosis (LAAT) detection should be limited to situations of absolute necessity. We sought to identify the main conventional and functional echocardiographic parameters associated with LAAT on TEE in non-valvular atrial fibrillation (NVAF) patients planned for electrical cardioversion (ECV). This retrospective study included 125 consecutive NVAF patients (71.5±7.8 yrs, 75 males), who underwent TEE at our Institution between April 2016 and January 2020, to exclude LAAT before scheduled ECV. All patients underwent a transthoracic echocardiography (TTE) implemented with speckle tracking echocardiography (STE) analysis of left atrial (LA) strain and strain rate (SR) parameters. 28% of patients were diagnosed with LAAT, while 72% without LAAT. Compared to controls, patients with LAAT had significantly higher CHA2DS2-Vasc Score and average E/e' ratio, and significantly lower left ventricular ejection fraction (LVEF). Moreover, LA-peak positive global atrial strain (GSA+) and LA-SR parameters were significantly reduced in patients with LAAT. Multivariate logistic regression revealed that, differently from CHA2DS2-Vasc Score, LVEF (OR 0.88, 95%CI 0.81-0.97, p = 0.01), average E/e' ratio (OR 2.36, 95%CI 1.41-3.98, p = 0.001), and LA-GSA+ (OR 0.57, 95%CI 0.36-0-90, p = 0.01) were independently associated with LAAT. LA-GSA+ (optimal cut-off ≤ 9.1%, AUC 0.95) showed the highest diagnostic performance. Finally, a strong linear correlation of LA peak-to-peak SR with both LA appendage filling (r = 0.86) and emptying (r = 0.83) velocities was demonstrated. TTE implemented with STE analysis of LA mechanics improves thrombotic risk assessment of NVAF patients.Entities:
Keywords: COVID-19; Electrical cardioversion; Left atrial appendage thrombosis; Left atrial strain; Non-valvular atrial fibrillation
Mesh:
Year: 2021 PMID: 33389359 PMCID: PMC7778706 DOI: 10.1007/s10554-020-02127-6
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Fig. 1Measurements of LA longitudinal strain (Panel a) and strain rate (Panel b) parameters by 2D-STE from the apical 4C-view in a NVAF patient enrolled in the present study. Panel A. Left atrial longitudinal strain parameters. Longitudinal strain curves of the seven atrial segments are depicted with different colors. The dotted line indicates the average atrial longitudinal strain. GSA+ (%): positive global atrial strain (yellow arrow from the maximal positive peak of the dotted line to the red line). 2D, two dimensional. LA left atrial, NVAF non-valvular atrial fibrillation, STE speckle tracking echocardiography. Panel B. Left atrial longitudinal SR parameters. The dotted line indicates the average SR. GSR+ (1/s), the first positive global strain rate, from the beginning of ventricular systole (yellow arrow from the maximal positive peak of the dotted line to the red line). GSR- (1/s), global early-diastolic strain rate (yellow arrow from the first maximal negative peak of the dotted line to the red line). SR strain rate
Main demographic and clinical characteristics of the whole study population and of two subgroups of patients, i.e. those with LAAT and those without
| Demographic and clinical parameters | All NVAF patients (n = 125) | NVAF pts with LAAT (n = 35) | NVAF pts without LAAT (n = 90) | p value |
|---|---|---|---|---|
| Age (yrs) | 71.5 ± 7.8 | 72.6 ± 8.1 | 71.0 ± 7.7 | 0.30 |
| Male sex (%) | 75 (60) | 19 (54.3) | 56 (62.2) | 0.42 |
| BSA (m2) | 1.91 ± 0.2 | 1.88 ± 0.2 | 1.93 ± 0.2 | 0.21 |
| Hypertension (%) | 86 (68.8) | 26 (74.3) | 60 (66.7) | 0.52 |
| Smokers (%) | 42 (33.6) | 12 (34.3) | 30 (33.3) | 0.91 |
| Type 2 diabetes (%) | 31 (24.8) | 11 (31.4) | 20 (22.2) | 0.18 |
| Dyslipidemia (%) | 69 (55.2) | 21 (60) | 48 (53.3) | 0.55 |
| History of CAD (%) | 30 (24) | 5 (14.3) | 25 (27.8) | 0.16 |
| Previous TIA/stroke (%) | 22 (17.6) | 12 (34.3) | 10 (11.1) | |
| CHA2DS2-Vasc Risk Score | 3.8 ± 1.24 | 4.5 ± 1.3 | 3.6 ± 1.1 | |
| Heart rate (bpm) | 81.3 ± 13.3 | 83.4 ± 13.5 | 80.5 ± 13.2 | 0.27 |
| VKAs (%) | 31 (24.8) | 8 (22.8) | 23 (25.5) | 0.82 |
| Therapeutic anticoagulation (%) | 24 (19.2) | 4 (11.4) | 20 (22.2) | 0.21 |
| NOACs (%) | 94 (75.2) | 26 (74.3) | 68 (75.5) | 0.88 |
| Antiplatelets (%) | 23 (18.4) | 4 (11.4) | 19 (21.1) | 0.30 |
| Antihypertensives (%) | 98 (78.4) | 28 (80) | 70 (77.8) | 0.98 |
| Beta blockers (%) | 64 (51.2) | 22 (62.8) | 42 (46.7) | 0.11 |
| Diuretics (%) | 66 (52.8) | 22 (62.8) | 44 (48.9) | 0.17 |
| Antiarrhythmics (%) | 59 (47.2) | 17 (48.6) | 42 (46.7) | 0.85 |
LAAT left atrial appendage thrombosis, NOACs novel oral anticoagulants, NVAF non-valvular atrial fibrillation, SEC spontaneous echo contrast, TIA transient ischemic attack, VKAs vitamin K antagonists, Data are expressed as mean ± SD or as number (percentage).
Significant p values are in bold. BSA, body surface area. CAD coronary artery disease, CHADS-VASc Congestive heart failure, Hypertension, Age at least 75 years (doubled), Diabetes, Stroke/transient ischemic attack/thromboembolism (doubled), Vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), Age 65–74 years, Sex category (female)
Main conventional and functional echocardiographic parameters assessed by 2D-TTE in the whole study population and in the two subgroups of patients, i.e. those with LAAT and those without
| Conventional and functional TTE parameters | All NVAF patients (n = 125) | NVAF pts with LAAT (n = 35) | NVAF pts without LAAT (n = 90) | p value |
|---|---|---|---|---|
| LVEDVi (ml/m2) | 42.2 ± 14.2 | 40.0 ± 13.5 | 43.0 ± 14.4 | 0.29 |
| RWT | 0.41 ± 0.1 | 0.42 ± 0.1 | 0.41 ± 0.1 | 0.61 |
| LVMi (g/m2) | 101.9 ± 29.3 | 103.6 ± 28.9 | 101.3 ± 29.6 | 0.69 |
| LVEF (%) | 54.4 ± 11.7 | 46.4 ± 14.5 | 57.5 ± 8.7 | |
| Average E/e’ ratio | 12.8 ± 4.7 | 18.4 ± 5.0 | 10.7 ± 2.0 | |
| LAVi (ml/m2) | 46.9 ± 10.6 | 48.4 ± 8.3 | 46.4 ± 11.3 | 0.34 |
| Av. LA-GSA + (%) | 13.1 ± 4.8 | 9.0 ± 2.5 | 14.8 ± 4.5 | |
| Av. Peak positive LA SR (s-1) | 1.65 ± 0.49 | 1.36 ± 0.21 | 1.78 ± 0.52 | |
| Av. Peak negative LA SR (s-1) | 0.90 ± 0.23 | 0.76 ± 0.24 | 0.96 ± 0.20 | |
| Av. Peak to peak LA SR (s-1) | 2.54 ± 0.58 | 2.12 ± 0.31 | 2.70 ± 0.57 | |
| Mild MR (%) | 95 (76) | 30 (85.7) | 65 (72.2) | 0.16 |
| Moderate MR (%) | 30 (24) | 5 (14.3) | 25 (27.8) | 0.16 |
| RVIT (mm) | 33.5 ± 5.4 | 34.5 ± 5.2 | 33.1 ± 5.5 | 0.20 |
| TAPSE (mm) | 18.2 ± 4.3 | 17.5 ± 4.1 | 18.5 ± 4.4 | 0.25 |
| SPAP (mmHg) | 37.7 ± 11.5 | 39.3 ± 11.2 | 37.0 ± 11.7 | 0.32 |
Significant p values are in bold. 2D, two-dimensional
Av average, GSA+ peak positive global atrial strain, LA left atrial, LAVi left atrial volume indexed, LAAT left atrial appendage thrombosis, LVEDVi left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVMi left ventricular mass indexed, MR mitral regurgitation, NVAF non-valvular atrial fibrillation, RVIT right ventricular inflow tract, RWT relative wall thickness, SEC spontaneous echo contrast, SPAP systolic pulmonary artery pressure, SR strain rate, STE speckle tracking echocardiography, TAPSE tricuspid annular plane systolic excursion, TTE transthoracic echocardiography. Data are expressed as mean ± SD or as number (percentage)
Main conventional echocardiographic parameters assessed by 2D-TEE in the whole study population and in the two subgroups of patients, i.e. those with LAAT and those without
| Conventional TEE parameters | All NVAF patients (n = 125) | NVAF pts with LAAT (n = 35) | NVAF pts without LAAT (n = 90) | p value |
|---|---|---|---|---|
| Presence of grade 4 SEC (%) | 15 (12) | 15 (43) | – | – |
| Presence of LAA thrombus (%) | 20 (16) | 20 (57) | – | – |
| LAA CW shape (%) | 42 (33.6) | 2 (5.7) | 40 (44.4) | |
| LAA WS shape (%) | 30 (24) | 5 (14.3) | 25 (27.8) | 0.16 |
| LAA CF shape (%) | 25 (20) | 10 (28.6) | 15 (16.7) | 0.14 |
| LAA Cactus shape (%) | 28 (22.4) | 18 (51.4) | 10 (11.1) | |
| LAA ostial diameter (mm) | 2.0 ± 0.3 | 2.1 ± 0.3 | 1.9 ± 0.3 | |
| LAA 2D-area (cm2) | 5.5 ± 1.9 | 6.5 ± 2.3 | 5.1 ± 1.6 | |
| LAA-EV (cm/s) | 47.3 ± 20.1 | 23.9 ± 3.9 | 56.5 ± 16.0 | |
| LAA- FV (cm/s) | 46.2 ± 20.0 | 26.3 ± 5.5 | 54.0 ± 18.1 |
Significant p values are in bold. 2D, two-dimensional
CF cauliflower, CW chicken wing, EV emptying velocity, FV filling velocity, LAA left atrial appendage, LAAT left atrial appendage thrombosis, NVAF non-valvular atrial fibrillation, SEC spontaneous echo contrast, TEE transesophageal echocardiography, WS windsock. Data are expressed as mean ± SD or as number (percentage).
Fig. 2Example of LA-GSA+ assessed by 2D-STE analysis, in a NVAF patient with LAAT enrolled in the present study. Yellow arrow indicates the LA-GSA+ value measured by 2D-STE analysis. This value (5.6%) was significantly depressed in comparison to controls and to the accepted normal ranges. 2D two-dimensional, GSA+ peak positive global atrial strain, LA left atrial, NVAF non-valvular atrial fibrillation, STE speckle tracking echocardiography
The factors associated with LAAT in univariate and multivariate logistic regression analysis
| Univariate logistic regression analysis | Multivariate logistic regression analysis | |||||
|---|---|---|---|---|---|---|
| Variables | OR | 95% CI | p value | OR | 95% CI | p value |
| CHA2DS2-Vasc Risk Score | 1.92 | 1.33–2.77 | 1.26 | 0.53–2.98 | 0.59 | |
| LVMi (g/m2) | 1.00 | 0.99–1.01 | 0.68 | |||
| LVEF (%) | 0.92 | 0.88–0.96 | 0.88 | 0.81–0.97 | ||
| Average E/e’ ratio | 2.25 | 1.64–3.10 | 2.36 | 1.41–3.98 | ||
| LAVi (ml/m2) | 1.02 | 0.98–1.05 | 0.35 | |||
| Average LA-GSA+ (%) | 0.59 | 0.47–0.74 | 0.57 | 0.36–0.90 | ||
| Moderate MR | 0.43 | 0.15–1.24 | 0.12 | |||
Significant p values are highlighted in bold
CHADS-VASc Congestive heart failure, Hypertension, Age at least 75 years (doubled), Diabetes, Stroke/transient ischemic attack/thromboembolism (doubled), Vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), Age 65–74 years, Sex category (female). Av average. CI confidence interval, LA left atrial, GSA+ peak positive global atrial strain, LAAT left atrial appendage thrombosis, LAVi left atrial volume index, LVEF left ventricular ejection fraction, LVMi left ventricular mass index, MR mitral regurgitation, OR odds ratio
ROC curves for the identifying of LAAT. 2D, two-dimensional. AUC, area under the curve
| ROC curves for the identifying of LAAT | |||||||
|---|---|---|---|---|---|---|---|
| VARIABLES | AUC | p value | Criterion of highest diagnostic value | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| CHA2DS2-VASc Risk Score | 0.71 | < 0.0001 | ≥ 4 | 83 | 50 | 62 | 75 |
| LVEF (%) | 0.73 | < 0.0001 | ≤ 45 | 49 | 89 | 82 | 63 |
| Average E/e’ ratio | 0.93 | < 0.0001 | ≥ 15 | 77 | 89 | 87 | 79 |
| Average LA-GSA+ (%) | 0.95 | < 0.0001 | ≤ 9.1 | 100 | 87 | 88 | 100 |
CHADS-VASc Congestive heart failure, Hypertension, Age at least 75 years (doubled), Diabetes, Stroke/transient ischemic attack/thromboembolism (doubled), Vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), Age 65–74 years, Sex category (female). LA left atrial, GSA+ peak positive global atrial strain, LVEF left ventricular ejection fraction, NPV negative predictive value, PPV predictive positive value, ROC receiver operating characteristics.
Fig. 3The correlation of peak-to-peak LA SR with LAA-FV (Panel a) and LAA-EV (Panel b) in the whole study population, evaluated by using the Pearson's correlation coefficient. EV emptying velocity, FV filling velocity, LA left atrial, LAA left atrial appendage, SR strain rate
Fig. 4Examples of grade 4 SEC (Panel a, yellow arrow) and thrombus (Panel b, yellow arrow) in the LAA detected by 2D-TEE examination in two NVAF patients enrolled in the present study